Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept

Table 1

Baseline characteristics of enrolled therapy switch patients.

Patients	RPE loss (mm^2)					Number of injections (N)
	One year; before switch	On switch; date	One year; after switch	Two years; after switch	Three years; after switch	Total	Prior to switch; 24 months	After switch; 24 months
P1	0.18	0.29	0.53	0.60	1.15	56	13	22
P2	0.23	0.27	0.35	0.42		53	22	21
P3	0.18	0.33	0.41	0.65	0.84	44	20	24
P4	1.44	2.88	3.25	3.85	3.94	28	19	4
P5	1.05	1.51	1.81	2.23		47	22	18
P6	0.35	0.54	0.69	0.75		30	16	17
P7	2.95	3.34	4.19	5.37		64	20	18
P8	2.82	3.06	3.40	3.80	3.79	53	12	17
P9	4.26	4.29	4.40	4.68		26	13	13
P10	1.02	1.07	1.80	2.01		39	16	23
P11	0.26	0.32	0.34	0.48	0.54	40	21	16
P12	0.97	1.13	1.37			61	22	12
P13	2.95	3.57	4.25	4.72		50	20	18
P14	1.93	2.48	2.94	3.34		44	21	11
P15	2.75	3.06	3.20			36	14	6
P16	3.38	3.52	5.17			46	23	7
P17	0.06	0.15	0.35			28	20	7
P18	0	0.55	0.66	1.06		9	5	4
P19	0	0.71	1.50	1.74	2.13	36	19	17